We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03207009
Recruitment Status : Active, not recruiting
First Posted : July 2, 2017
Last Update Posted : February 21, 2022
Sponsor:
Information provided by (Responsible Party):
bluebird bio

Tracking Information
First Submitted Date  ICMJE June 29, 2017
First Posted Date  ICMJE July 2, 2017
Last Update Posted Date February 21, 2022
Actual Study Start Date  ICMJE June 8, 2017
Estimated Primary Completion Date November 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 4, 2022)
Proportion of Participants who meet the Definition of Transfusion Independence (TI) [ Time Frame: From 12 to 24 months post-transplant ]
TI is defined as greater than or equal to (>=) 9 grams per deciliter (g/dL) without any packed red blood cell (pRBC) transfusions for a continuous period of >=12 months at any time during the study after drug product infusion.
Original Primary Outcome Measures  ICMJE
 (submitted: June 29, 2017)
The proportion of subjects who meet the definition of "transfusion reduction" (TR). [ Time Frame: 24 months post-transplant ]
TR is defined as demonstration of reduction in volume of RBC transfusion requirements (in mL/kg) in the post-treatment time period of Months 12 to 24 compared to the average annual transfusion requirement in the 24 months prior to enrollment.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 4, 2022)
  • Proportion of Participants who meet the Definition of Transfusion Independence (TI) at Month 24 [ Time Frame: At Month 24 post-transplant ]
  • Duration of Transfusion Independence (TI) [ Time Frame: Up to 24 months post-transplant ]
  • Time From Drug Product Infusion to Achievement of Transfusion Independence (TI) [ Time Frame: From 12 to 24 months post-transplant ]
  • Average Weighted Hemoglobin (Hb) During Transfusion Independence (TI) [ Time Frame: From 12 to 24 months post-transplant ]
  • Proportion of Participants who meet the Definition of Transfusion Reduction (TR) [ Time Frame: From 12 to 24 months post-transplant ]
    TR is defined as demonstration of a 60 percent (%) reduction in the annualized volume of pRBC transfusion requirements (in milliliter per kilogram [mL/kg]) in the post-treatment time period from 12 Months post-drug product infusion through Month 24 compared to the annualized mL/kg pRBC transfusion requirement during the 24 months prior to study enrollment
  • Proportion of Participants with At Least 50%, 60%, 75%, 90% or 100% Reduction in the Annualized pRBCs Transfusion [ Time Frame: From 12 to 24 months post-transplant ]
    Reduction in the annualized mL/kg pRBCs transfused from 12 months post-drug product infusion through Month 24 (approximately a 12-month period) of at least 50%, 60%, 75%, 90% or 100% compared to the annualized mL/kg pRBC transfusion requirement during the 24 months prior to enrollment.
  • Annualized Number of pRBC Transfusions [ Time Frame: From 12 to 24 months post-transplant ]
    Annualized number of pRBC transfusions from 12 months post-drug product infusion through Month 24 compared to the annualized number of transfusions during the 24 months prior to enrollment.
  • Annualized Volume of pRBC Transfusions [ Time Frame: From 12 to 24 months post-transplant ]
    Annualized volume of pRBC transfusions from 12 months post-drug product infusion through Month 24 compared to the annualized volume of transfusions during the 24 months prior to enrollment.
  • Time From Drug Product Infusion to Last pRBC Transfusion [ Time Frame: Up to 24 months post-transplant ]
  • Time From Last pRBC Transfusion to 24 Months [ Time Frame: Up to 24 months post-transplant ]
  • Weighted Average Nadir Hemoglobin (Hb) [ Time Frame: From 12 to 24 months post-transplant ]
    Weighted average nadir Hb during the 24 months prior to enrollment compared to weighted average nadir Hb from 12 months post-drug product infusion through the Month 24 Visit.
  • Unsupported Total Hb Levels Over Time [ Time Frame: At Month 6, 9, 12, 18 and 24 ]
  • Unsupported Total Hb Levels (>=10 g/dL, >=11 g/dL, >=12 g/dL, >=13 g/dL, and >=14 g/dL) [ Time Frame: At Month 6, 12, 18 and 24 ]
  • Proportion of Participants Who Have Not Received Chelation Therapy for At Least 6 Months Following Drug Product Infusion [ Time Frame: From 6 to 24 months ]
  • Time From Last Iron Chelation Use to Last Follow-up [ Time Frame: Up to 24 months ]
  • Proportion of Participants Using Therapeutic Phlebotomy and Annualized Frequency of Phlebotomy [ Time Frame: Up to 24 months ]
  • Change From Baseline in Liver Iron Content by Magnetic Resonance Imaging (MRI) [ Time Frame: Baseline, Month 12 and 24 ]
  • Change From Baseline in Cardiac T2 on MRI [ Time Frame: Baseline, Month 12 and 24 ]
  • Change From Baseline in Serum Ferritin [ Time Frame: Baseline, Month 12 and 24 ]
  • Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Score [ Time Frame: Baseline, Month 12 and 24 ]
    PedsQL GCS is designed to measure health-related quality of life in pediatric participants and adolescents (2 to 18 years of age). It encompasses 4 dimensions of functioning (physical [8 items], emotional [5 items], social [5 items], school [3 items]). Age groups: Toddler (2-4 years), Young pediatric (5-7 years), Pediatric (8-12 years), and Teens (13-18 years). Depending on the participant's age, the questionnaire may be completed by parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consist of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consist of 23 items, with a 3-point Likert scale (0, 2, 4) for the young pediatric, and a 5-point Likert scale for the pediatric and teens groups. Scores are transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.
  • Change From Baseline in EuroQol-5D (Youth version) (EQ-5D-Y) [ Time Frame: Baseline, Month 12 and 24 ]
    EQ-5D-Y health questionnaire is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.
  • Change From Baseline in EuroQol-5D (EQ-5D) [ Time Frame: Baseline, Month 12 and 24 ]
    The EQ-5D provides a descriptive profile and index value for health status. The questionnaire measures 5 dimensions of health status: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, there are 5 levels of response: no problems, slight problems, moderate problems, severe problems, and unable to do/extreme problems.
  • Change From Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Questionnaire Score [ Time Frame: Baseline, Month 12 and 24 ]
    The FACT-BMT assesses bone marrow transplant related concerns. The total score is the sum of sub-scale scores for 5 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, and Bone Marrow Transplantation Subscale. Within each domain, a 5-point Likert-type scale (from 0-4) is used to measure the responses for each question. After taking into account reverse scores for questions constructed in a negative form, the subscale score for each domain is calculated by multiplying the sum of the item scores by the number of items in the subscale, then dividing by the number of items answered. The final score for FACT-BMT ranges from 0 to 148. Higher scores indicate better quality of life.
  • Change From Baseline in Short Form-36 Health Survey (SF-36), Version 2 [ Time Frame: Baseline, Month 12 and 24 ]
    SF-36 is a generic quality-of-life instrument that had been widely used to assess HRQL of participants. Generic instruments were used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consisted of 36 items that were aggregated into 8 multi-item scales (physical functioning [1=yes, limited a lot to 3=no, not limited at all], role-physical [1=all of the time to 5=none of the time], bodily pain [1=very severe to 6=none], general health [1=poor to 5=excellent], vitality [1=none of the time to 5=all of the time], social functioning [1=all of the time: to 5=none of the time], role emotional [1=all of the time to 5=none of the time] and mental health [1=all of the time to 5=none of the time]), with scores ranged from 0 to 100. Higher scores indicating better HRQL.
Original Secondary Outcome Measures  ICMJE
 (submitted: June 29, 2017)
  • The proportion of treated subjects who meet the definition of "transfusion independence" (TI). TI is defined as Hb ≥9g/dL without any RBC transfusions for a continuous period of ≥12 months at any time during the study after drug product infusion. [ Time Frame: 12-24 months post-transplant ]
  • Percentage of subjects with a reduction in the mL/kg RBC transfused from Month 12 through Month 24 after drug product infusion of at least 50% compared to the average annual RBC transfusion requirement during the 2 years prior to enrollment. [ Time Frame: 24 months post-transplant ]
  • Frequency of events of insertional mutagenesis leading to clonal dominance or leukemia. [ Time Frame: 24 months post-transplant ]
  • Frequency of clinical adverse events [ Time Frame: 24 months post-transplant ]
  • Detection of vector-derived replication competent lentivirus (RCL) using a RCL screening assay [ Time Frame: 24 months post-transplant ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia
Official Title  ICMJE A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects With Transfusion-dependent β-Thalassemia by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector in Subjects ≤50 Years of Age
Brief Summary This is a single-arm, multi-site, single-dose, Phase 3 study in approximately 18 participants less than or equal to (<=) 50 years of age with transfusion-dependent β-thalassemia (TDT), who have a β0/β0, β0/IVS-I-110, or IVS-I-110/IVS-I-110 genotype. The study will evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation (HSCT) using LentiGlobin BB305 Drug Product.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Beta-Thalassemia
Intervention  ICMJE Genetic: LentiGlobin BB305 Drug Product
LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
Other Name: betibeglogene autotemcel
Study Arms  ICMJE Experimental: LentiGlobin BB305 Drug Product
LentiGlobin BB305 Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with LentiGlobin BB305 lentiviral vector encoding human βA-T87Q-globin)
Intervention: Genetic: LentiGlobin BB305 Drug Product
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: November 22, 2019)
18
Original Estimated Enrollment  ICMJE
 (submitted: June 29, 2017)
15
Estimated Study Completion Date  ICMJE November 2022
Estimated Primary Completion Date November 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

• Participants less than or equal to (<=) 50 years of age at the time of consent or assent (as applicable), and able to provide written consent (adults, or legal guardians, as applicable) or assent (adolescents or children). Provided that the data monitoring committee (DMC) has approved enrolling participants younger than 5 years of age, participants younger than 5 years of age may be enrolled if they weigh a minimum of 6 kilograms (kg) and are reasonably anticipated to be able to provide at least the minimum number of cells required to initiate the manufacturing process.

  • Diagnosis of TDT with a history of at least 100 milliliter per kilogram per year (mL/kg/year) of pRBCs in the 2 years preceding enrollment (all participants), or be managed under standard thalassemia guidelines with >= 8 transfusions of pRBCs per year in the 2 years preceding enrollment (participants >=12 years).
  • Clinically stable and eligible to undergo HSCT.
  • Treated and followed for at least the past 2 years in a specialized center that maintained detailed medical records, including transfusion history.

Exclusion Criteria:

  • Presence of a mutation characterized as other then β0 (e.g., β+, βE, βC) on at least one β-globin gene (HBB) allele.
  • Positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 and HIV-2), hepatitis B virus (HBV), or hepatitis C (HCV).
  • A white blood cell (WBC) count less than (<) 3×10^9/liter (L), and/or platelet count <100×10^9/L not related to hypersplenism.
  • Uncorrected bleeding disorder.
  • Any prior or current malignancy.
  • Prior HSCT.
  • Advanced liver disease.
  • A cardiac T2* <10 ms by MRI.
  • Any other evidence of severe iron overload that, in the investigator's opinion, warrants exclusion.
  • Participation in another clinical study with an investigational drug within 30 days of Screening.
  • Any other condition that would render the participant ineligible for HSCT, as determined by the attending transplant physician or investigator.
  • Prior receipt of gene therapy.
  • Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception for fertile participant.
  • A known and available human leukocyte antigen (HLA) matched family donor.
  • Any contraindications to the use of granulocyte colony stimulating factor (G-CSF) and plerixafor during the mobilization of hematopoietic stem cells and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 0 Years to 50 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France,   Germany,   Greece,   Italy,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03207009
Other Study ID Numbers  ICMJE HGB-212
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party bluebird bio
Original Responsible Party Same as current
Current Study Sponsor  ICMJE bluebird bio
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Himal L Thakar, MD bluebird bio
PRS Account bluebird bio
Verification Date February 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP